All Stories

  1. Digital front door technologies to pre-assess people before assessment for NHS Talking Therapies [HTE10055]: early value assessment

    Article • Health Technology Assessment, June 2026, National Institute for Health Research

    Mr Nigel David Fleeman

  2. Service delivery, behavioural, and self-management interventions for children with epilepsy

    Article • Cochrane Database of Systematic Reviews, October 2025, Wiley

    Mr Nigel David Fleeman

  3. Service delivery, behavioural, and self-management interventions for adults with epilepsy

    Article • Cochrane Database of Systematic Reviews, September 2025, Wiley

    Mr Nigel David Fleeman

  4. Lenvatinib plus pembrolizumab for untreated advanced renal cell carcinoma: a systematic review and cost-effectiveness analysis

    Article • Health Technology Assessment, August 2024, National Institute for Health Research

    Mr Nigel David Fleeman

  5. Estimated health effects from domestic use of gaseous fuels for cooking and heating in high-income, middle-income, and low-income countries: a systematic review and meta-analyses

    Article • The Lancet Respiratory Medicine, April 2024, Elsevier

    Mr Nigel David Fleeman

  6. Correction: Onasemnogene Abeparvovec for Treating Pre-symptomatic Spinal Muscular Atrophy: An External Assessment Group Perspective of the Partial Review of NICE Highly Specialised Technology Evaluation 15

    Article • PharmacoEconomics - Open, November 2023, Springer Science + Business Media

    Mr Nigel David Fleeman

  7. Onasemnogene Abeparvovec for Treating Pre-symptomatic Spinal Muscular Atrophy: An External Assessment Group Perspective of the Partial Review of NICE Highly Specialised Technology Evaluation 15

    Article • PharmacoEconomics - Open, September 2023, Springer Science + Business Media

    Mr Nigel David Fleeman

  8. Pegcetacoplan for Treating Paroxysmal Nocturnal Haemoglobinuria: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

    Article • PharmacoEconomics - Open, May 2023, Springer Science + Business Media

    Mr Nigel David Fleeman

  9. Trastuzumab Deruxtecan for Treating HER2-Positive Unresectable or Metastatic Breast Cancer After Two or More Anti-HER2 Therapies: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

    Article • PharmacoEconomics - Open, April 2023, Springer Science + Business Media

    Mr Nigel David Fleeman

  10. Service delivery, behavioural, and self-management interventions for adults with epilepsy

    Article • Cochrane Database of Systematic Reviews, March 2023, Wiley

    Mr Nigel David Fleeman

  11. Service delivery, behavioural, and self-management interventions for children with epilepsy

    Article • Cochrane Database of Systematic Reviews, March 2023, Wiley

    Mr Nigel David Fleeman

  12. Health effects of liquid and gaseous fuels for household energy use: Systematic evidence mapping

    Article • Environmental Research Letters, November 2022, Institute of Physics Publishing

    Dr Rui Duarte, Mr Nigel David Fleeman

  13. Health Effects of Liquid and Gaseous Fuels for Household Energy Use: Systematic Evidence Mapping

    Article • October 2022, Springer Science + Business Media

    Mr Nigel David Fleeman

  14. Care delivery and self-management strategies for children with epilepsy

    Article • Cochrane Database of Systematic Reviews, April 2022, Wiley

    Mr Nigel David Fleeman

  15. Are cleaner cooking solutions clean enough? A systematic review and meta-analysis of particulate and carbon monoxide concentrations and exposures

    Article • Environmental Research Letters, July 2021, Institute of Physics Publishing

    Dr Rui Duarte, Mr Nigel David Fleeman

  16. A systematic review of health state utility values for thyroid cancer

    Article • Quality of Life Research, October 2020, Springer Science + Business Media

    Dr Rui Duarte, Mr Nigel David Fleeman

  17. Brentuximab Vedotin for Treating Relapsed or Refractory CD30-Positive Cutaneous T-Cell Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

    Article • PharmacoEconomics - Open, March 2020, Springer Science + Business Media

    Mr Nigel David Fleeman

  18. Lenvatinib and sorafenib for differentiated thyroid cancer after radioactive iodine: a systematic review and economic evaluation

    Article • Health Technology Assessment, January 2020, National Institute for Health Research

    Dr Rui Duarte, Mr Nigel David Fleeman

  19. A systematic review of lenvatinib and sorafenib for treating progressive, locally advanced or metastatic, differentiated thyroid cancer after treatment with radioactive iodine

    Article • BMC Cancer, December 2019, Springer Science + Business Media

    Dr Rui Duarte, Mr Nigel David Fleeman

  20. Cenegermin for Treating Neurotrophic Keratitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

    Article • PharmacoEconomics - Open, June 2019, Springer Science + Business Media

    Dr Rui Duarte, Mr Nigel David Fleeman

  21. Eribulin for Treating Locally Advanced or Metastatic Breast Cancer After One Chemotherapy Regimen: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

    Article • PharmacoEconomics - Open, February 2019, Springer Science + Business Media

    Dr Rui Duarte, Mr Nigel David Fleeman

  22. Heated Humidified High-Flow Nasal Cannula for Preterm Infants: An Updated Systematic Review and Meta-analysis

    Article • International Journal of Technology Assessment in Health Care, January 2019, Cambridge University Press

    Mr Nigel David Fleeman

  23. Care delivery and self-management strategies for children with epilepsy

    Article • Cochrane Database of Systematic Reviews, March 2018, Wiley

    Mr Nigel David Fleeman

  24. Pegylated Liposomal Irinotecan Hydrochloride Trihydrate for Treating Pancreatic Cancer After Gemcitabine: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

    Article • PharmacoEconomics, November 2017, Springer Science + Business Media

    Mr Nigel David Fleeman

  25. An assessment of the impact of pharmacogenomics on health disparities: a systematic literature review

    Article • Pharmacogenomics, November 2017, Future Medicine

    Jennifer Downing, Mr Nigel David Fleeman

  26. Talimogene Laherparepvec for Treating Metastatic Melanoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

    Article • PharmacoEconomics, March 2017, Springer Science + Business Media

    Mr Nigel David Fleeman

  27. The clinical effectiveness and cost-effectiveness of heated humidified high-flow nasal cannula compared with usual care for preterm infants: systematic review and economic evaluation

    Article • Health Technology Assessment, April 2016, National Institute for Health Research

    Mr Nigel David Fleeman

  28. Care delivery and self management strategies for adults with epilepsy

    Article • Cochrane Database of Systematic Reviews, February 2016, Wiley

    Mr Nigel David Fleeman

  29. Care delivery and self management strategies for children with epilepsy

    Article • Cochrane Database of Systematic Reviews, December 2015, Wiley

    Mr Nigel David Fleeman

  30. Moderators of the effect of psychological interventions on depression and anxiety in cardiac surgery patients: A systematic review and meta-analysis

    Article • Behaviour Research and Therapy, October 2015, Elsevier

    Mr Nigel David Fleeman, Dr Cleo Protogerou

  31. The clinical effectiveness and cost-effectiveness of the PROGENSA® prostate cancer antigen 3 assay and the Prostate Health Index in the diagnosis of prostate cancer: a systematic review and economic evaluation

    Article • Health Technology Assessment, October 2015, National Institute for Health Research

    Mr Nigel David Fleeman

  32. Economic evaluations of personalized medicine: existing challenges and current developments

    Article • Pharmacogenomics and Personalized Medicine, June 2015, Taylor & Francis

    Mr Nigel David Fleeman

  33. Dabrafenib for Treating Unresectable, Advanced or Metastatic BRAF V600 Mutation-Positive Melanoma: An Evidence Review Group Perspective

    Article • PharmacoEconomics, April 2015, Springer Science + Business Media

    Mr Nigel David Fleeman

  34. Prasugrel (Efient®) with percutaneous coronary intervention for treating acute coronary syndromes (review of TA182): systematic review and economic analysis

    Article • Health Technology Assessment, April 2015, National Institute for Health Research

    Mr Nigel David Fleeman

  35. Deferasirox for managing iron overload in people with myelodysplastic syndrome

    Article • Cochrane Database of Systematic Reviews, October 2014, Wiley

    Dr Joerg Meerpohl, Mr Nigel David Fleeman

  36. Eribulin for the Treatment of Advanced or Metastatic Breast Cancer: A NICE Single Technology Appraisal

    Article • PharmacoEconomics, September 2014, Springer Science + Business Media

    Mr Nigel David Fleeman

  37. Pertuzumab in Combination with Trastuzumab and Docetaxel for the Treatment of HER2-Positive Metastatic or Locally Recurrent Unresectable Breast Cancer

    Article • PharmacoEconomics, August 2014, Springer Science + Business Media

    Mr Nigel David Fleeman

  38. Deferasirox for managing transfusional iron overload in people with sickle cell disease

    Article • Cochrane Database of Systematic Reviews, June 2014, Wiley

    Dr Joerg Meerpohl, Mr Nigel David Fleeman

  39. Allopurinol for the treatment of chronic kidney disease: asystematic review

    Article • Health Technology Assessment, June 2014, National Institute for Health Research

    Mr Nigel David Fleeman

  40. Are health technology assessments of pharmacogenetic tests feasible? A case study ofCYP2D6testing in the treatment of breast cancer with tamoxifen

    Article • Personalized Medicine, August 2013, Future Medicine

    Mr Nigel David Fleeman

  41. Deferasirox for managing iron overload in people with thalassaemia

    Article • February 2012, Wiley

    Dr Joerg Meerpohl, Mr Nigel David Fleeman

  42. The clinical effectiveness and cost-effectiveness of genotyping for CYP2D6 for the management of women with breast cancer treated with tamoxifen: a systematic review.

    Article • Health Technology Assessment, September 2011, National Institute for Health Research

    Mr Nigel David Fleeman

  43. Cetuximab nel carcinoma ricorrente e/o metastatico a cellule squamose della testa e del collo. Una valutazione di tecnologia singola del NICE

    Article • PharmacoEconomics Italian Research Articles, July 2011, Springer Science + Business Media

    Mr Nigel David Fleeman

  44. Deferasirox for managing iron overload in people with myelodysplastic syndrome

    Article • November 2010, Wiley

    Dr Joerg Meerpohl, Mr Nigel David Fleeman

  45. Pemetrexed for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer

    Article • Health Technology Assessment, October 2010, National Institute for Health Research

    Mr Nigel David Fleeman

  46. Cytochrome P450 testing for prescribing antipsychotics in adults with schizophrenia: systematic review and meta-analyses

    Article • The Pharmacogenomics Journal, September 2010, Springer Science + Business Media

    Mr Nigel David Fleeman

  47. Deferasirox for managing transfusional iron overload in people with sickle cell disease

    Article • August 2010, Wiley

    Dr Joerg Meerpohl, Mr Nigel David Fleeman

  48. Cetuximab for Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck

    Article • PharmacoEconomics, June 2010, Springer Science + Business Media

    Mr Nigel David Fleeman, Adrian Bagust

  49. Pemetrexed for the first-line treatment of locally advanced or metastatic non-small cell lung cancer

    Article • Health Technology Assessment, May 2010, National Institute for Health Research

    Mr Nigel David Fleeman

  50. Prasugrel for the treatment of acute coronary artery syndromes with percutaneous coronary intervention

    Article • Health Technology Assessment, May 2010, National Institute for Health Research

    Mr Nigel David Fleeman

  51. Prasugrel for the treatment of acute coronary artery syndromes with percutaneous coronary intervention

    Article • Health Technology Assessment, May 2010, National Institute for Health Research

    Mr Nigel David Fleeman

  52. The clinical effectiveness and cost-effectiveness of testing for cytochrome P450 polymorphisms in patients with schizophrenia treated with antipsychotics: a systematic review and economic evaluation

    Article • Health Technology Assessment, January 2010, National Institute for Health Research

    Mr Nigel David Fleeman

  53. Cetuximab for the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck

    Article • Health Technology Assessment, October 2009, National Institute for Health Research

    Mr Nigel David Fleeman

  54. Rituximab for the treatment of rheumatoid arthritis

    Article • Health Technology Assessment, September 2009, National Institute for Health Research

    Mr Nigel David Fleeman

  55. Providing patients with information on pharmacogenetic testing

    Article • Nursing Standard, January 2009, RCNi

    Mr Nigel David Fleeman

  56. Providing patients with information on pharmacogenetic testing

    Article • Nursing Standard, January 2009, RCNi

    Mr Nigel David Fleeman

  57. Deferasirox for the treatment of iron overload associated with regular blood transfusions (transfusional haemosiderosis) in patients suffering with chronic anaemia: a systematic review and economic evaluation

    Article • Health Technology Assessment, January 2009, National Institute for Health Research

    Mr Nigel David Fleeman

  58. Deferasirox for managing transfusional iron overload in people with sickle cell disease

    Article • October 2008, Wiley

    Dr Joerg Meerpohl, Mr Nigel David Fleeman

  59. Deferasirox for managing iron overload in people with thalassaemia

    Article • October 2008, Wiley

    Dr Joerg Meerpohl, Mr Nigel David Fleeman

  60. Deferasirox for managing iron overload in patients with myelodysplastic syndrome

    Article • October 2008, Wiley

    Dr Joerg Meerpohl, Mr Nigel David Fleeman

  61. So many filters, so little time: the development of a search filter appraisal checklist

    Article • Journal of the Medical Library Association JMLA, October 2008, Medical Library Association

    Mr Nigel David Fleeman, Ms Julie Glanville

  62. A prospective health impact assessment of the Merseyside Integrated Transport Strategy (MerITS)

    Article • Journal of Public Health, September 2000, Oxford University Press (OUP)

    Mr Nigel David Fleeman

  63. ALCOHOL HOME DETOXIFICATION: A LITERATURE REVIEW

    Article • Alcohol and Alcoholism, November 1997, Oxford University Press (OUP)

    Mr Nigel David Fleeman